<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01076140</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0222</org_study_id>
    <nct_id>NCT01076140</nct_id>
  </id_info>
  <brief_title>Blood Pressure Effects of Nebivolol Versus Lisinopril in New Onset or Worsening Hypertension Induced by Bevacizumab</brief_title>
  <official_title>Comparative Blood Pressure Effects of Nebivolol Versus Lisinopril in Patients With New Onset or Exacerbated Hypertension Induced by Bevacizumab: a Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Mississippi Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to directly compare the blood pressure (hypertension) reduction
      effects of lisinopril and nebivolol in patients who develop new onset or worsening
      hypertension while treated with bevacizumab.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants enrolled
  </why_stopped>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">August 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of the study will be changes in sitting systolic and diastolic blood pressure at the crossover and final visits.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Patients will be treated with both nebivolol or lisinopril for a period of 4 weeks, and then crossover to the opposite medication for an additional 4 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary endpoint of the study will be changes in heart rate at the end of the crossover and final visits.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Patients will be treated with both nebivolol or lisinopril for a period of 4 weeks, and then crossover to the opposite medication for an additional 4 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nebivolol 5 mg daily for 2 weeks, then 5 or 10 mg daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lisinopril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg once daily for 2 weeks, then 20 or 40 mg once daily for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol</intervention_name>
    <description>Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks</description>
    <arm_group_label>Nebivolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril</intervention_name>
    <description>Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks</description>
    <arm_group_label>Lisinopril</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients currently treated at the University of Mississippi Medical Center Oncology
             Clinic

          -  Patient is being treated with bevacizumab either alone or in combination with other
             agents for cancer

          -  Patient blood pressure is &gt;140 mmHg (systolic) or &gt; 90 mmHg (diastolic), either
             treated or untreated with medications for hypertension

          -  Patients may be currently on medications for hypertension (other than Beta blocker,
             ACEI, or ARB); these will be continued at the same dose throughout the study

          -  Patients should be &gt; 18 years of age

          -  Patients receiving bevacizumab therapy approximately every 2 weeks

        Exclusion Criteria:

          -  History of ACEI or ARB induced angioedema or idiopathic/hereditary angioedema

          -  Patient currently treated with a Beta blocker, ACEI, or ARB or have a history of
             intolerance to a medication in any of these classes

          -  Hyperkalemia, defined as a potassium value of &gt;5 mEq/L

          -  Pregnancy or breastfeeding

          -  Severe renal impairment (eGFR &lt;30 mL/min)

          -  Moderate hepatic impairment as identified by physician

          -  Currently taking CYP2D6 inducers (rifampin, carbamazepine or dexamethasone) or
             inhibitors (bupropion, fluoxetine, paroxetine, duloxetine, etc.)

          -  History of clinically significant EKG abnormality which would contraindicate beta
             blocker use

          -  Recent stroke (&lt;6 months)

          -  Recent myocardial infarction (&lt;6 months)

          -  Congestive heart failure

          -  Severe asthma or COPD

          -  Diagnosed obstructive sleep apnea
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2010</study_first_submitted>
  <study_first_submitted_qc>February 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2010</study_first_posted>
  <last_update_submitted>April 5, 2012</last_update_submitted>
  <last_update_submitted_qc>April 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Mississippi Medical Center</investigator_affiliation>
    <investigator_full_name>Zachery Somers</investigator_full_name>
    <investigator_title>PharmD</investigator_title>
  </responsible_party>
  <keyword>Hypertension as a result of bevacizumab therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

